Table 4.
First Incidence of NEs by Blinatumomab Css in Cycle 1
| 1st Css quartile | 2nd Css quartile | 3rd Css quartile | 4th Css quartile | |
|---|---|---|---|---|
| Treatment during the first 7 days (9 μg/day) | ||||
| Median (range) Css, pg/mL | 68 (51–80) | 109 (83–132) | 147 (132–206) | 387 (214–1782) |
| Number of patients with NEs, n/N (%) | 5/21 (24) | 3/21 (14) | 7/21 (33) | 10/22 (45) |
| Treatment after 7 days (28 μg/day) | ||||
| Median (range) Css, pg/mL | 175 (57–264) | 398 (266–494) | 623 (494–815) | 982 (821–2838) |
| Number of patients with NEs, n/N (%) | 9/34 (26) | 12/34 (35) | 16/33 (48) | 17/34 (50) |
Css steady-state concentration, NE neurologic event
n the number of patients who had the first incidence of NE at any grade and quantifiable Css values, N the total number of patients who had quantifiable Css